Antibodies
TG100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively.
| Size | Price | Stock | Quantity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
| Description | TG100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively. | |||||
|---|---|---|---|---|---|---|
| Targets | PI3Kγ | PI3Kδ | PI3Kα | PI3Kβ | ||
| IC50 | 50 nM | 24 nM | 165 nM | 215 nM [1] | ||
| In vitro | TG 100713 also strongly inhibits EC proliferation. [1] | |||||
| In vivo | ||||||
| Features | ||||||
| Kinase Assays | PI3K reactions are constructed by using recombinant human kinases, 3 μM ATP, phosphatidylinositol substrate, and cofactors, and reaction progression measured by using a luminescent-based detection system to quantify ATP consumption. Protein kinase assays are performed by using commercial screening services. |
|---|
| Cell lines | HUVEC |
|---|---|
| Concentrations | 10 μM |
| Incubation Time | 24, 48, 72 h |
| Method | Human umbilical vein EC plated in 96-well cluster plates (5,000 cells/well) are cultured in assay medium (containing 0.5% serum and 50 ng/ml VEGF) in the presence or absence of test compounds (10 μM), and cell numbers are quantified by XTT assay. |
| Molecular Weight (MW) | 254.25 |
|---|---|
| Formula | C12H10N6 |
| CAS No. | 925705-73-3 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | N/A |
| Solubility (25°C) * | In vitro | DMSO | 2 mg/mL (7 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | Phenol, 3-(2,4-diamino-6-pteridinyl)- |
|---|
![]() Click to enlarge | Rating | |
| Source | Dr Antonino Maria Spartà from University of Bologna.TG100713 purchased from Selleck | |
| Method | MTT | |
| Cell Lines | Jurkat E6.1 | |
| Concentrations | ||
| Incubation Time | 48 h | |
| Results | The compounds BAY80-6946 and TG100713, which are respectively an alpha/beta- and a pan-isoforms inhibitors, demonstrated a very good ability to block Jurkat E6.1 proliferation with an IC50 slightly higher than 1 mM. |